The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a battle that has now gone on for five months.
Continue reading Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More
Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More originally appeared on DailyFinance on Mon, 20 Dec 2010 10:50:00.
Filed Under: Company News, Genzyme Corporation , Sanofi Aventis, Stocks in the News